Dr. Aaron Lisberg, MD
Hematology & Oncology (Hematology & Oncology Physician)
2020 Santa Monica Blvd Ste 600
Santa Monica, CA 90404
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 68
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Minnesota Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A131055 (first issued 2014; current) -
Internal Medicine Physician
CA license A131055 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ronald Reagan UCLA Medical Center Los Angeles, CA
- Santa Monica - UCLA Med Ctr & Orthopaedic Hospital Santa Monica, CA
Medical groups
- The Regents of the University of California (1,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 68
- Services billed
- 6,584
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 270 | 12 |
| Blood test, comprehensive group of blood chemicals | 101 | 44 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 100 | 46 |
| Established patient office or other outpatient visit, 40-54 minutes | 81 | 39 |
| Infusion, normal saline solution, 250 cc | 50 | 15 |
| Administration of chemotherapy into vein, 1 hour or less | 41 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 30 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 40 |
| Dexamethasone Other prescribers in Santa Monica, CA | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 27 payments worth $60,129 in total to this clinician.
| BioNTech SE | $19,749 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $11,239 |
| Aadi Bioscience, Inc. | $10,800 |
| AbbVie Inc. | $8,216 |
| Daiichi Sankyo Inc. | $5,125 |
| E.r. Squibb & Sons, L.l.c. | $3,215 |
| AstraZeneca UK Limited | $1,025 |
| Gilead Sciences, Inc. | $760 |
| Consulting Fee | $38,562 |
|---|---|
| Travel and Lodging | $20,154 |
| Compensation for services other than consulting (speaking, faculty) | $1,083 |
| Food and Beverage | $330 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| BioNTech SE Feb 6, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $17,347 |
| AbbVie Inc. Feb 14, 2025 | Consulting Fee | $7,975 |
| Aadi Bioscience, Inc. Sep 26, 2025 | Consulting Fee Fyarro · Cancer | $6,600 |
| Daiichi Sankyo Inc. Aug 29, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $5,125 |
| AstraZeneca Pharmaceuticals LP Dec 6, 2025 | Consulting Fee DATROWAY · Oncology | $3,797 |
| Aadi Bioscience, Inc. Dec 8, 2025 | Consulting Fee Fyarro · Cancer | $3,000 |
| AstraZeneca Pharmaceuticals LP Dec 6, 2025 | Consulting Fee | $2,460 |
| E.r. Squibb & Sons, L.l.c. Jul 7, 2025 | Consulting Fee | $2,400 |
| AstraZeneca Pharmaceuticals LP Jun 19, 2025 | Consulting Fee | $1,230 |
| Aadi Bioscience, Inc. Nov 14, 2025 | Consulting Fee Fyarro · Cancer | $1,200 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 24, 2025 | Travel and Lodging travel to chicago, IL Company’s descriptionConsulting Expenses | $209 |
| AstraZeneca UK Limited Dec 23, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $1,025 |
| Aadi Bioscience, Inc. Dec 8, 2025 | Consulting Fee Fyarro · Cancer | $3,000 |
| AstraZeneca Pharmaceuticals LP Dec 6, 2025 | Consulting Fee DATROWAY · Oncology | $3,797 |
| AstraZeneca Pharmaceuticals LP Dec 6, 2025 | Consulting Fee | $2,460 |
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Travel and Lodging travel to Chicago, IL · in-kind Company’s descriptionConsulting Expenses | $931 |
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Consulting Fee DATROWAY · Oncology | $820 |
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Travel and Lodging travel to Chicago, IL · in-kind Company’s descriptionConsulting Expenses | $210 |
| Aadi Bioscience, Inc. Nov 14, 2025 | Consulting Fee Fyarro · Cancer | $1,200 |
| Aadi Bioscience, Inc. Sep 26, 2025 | Consulting Fee Fyarro · Cancer | $6,600 |
| Daiichi Sankyo Inc. Aug 29, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $5,125 |
| E.r. Squibb & Sons, L.l.c. Jul 24, 2025 | Consulting Fee | $800 |
| E.r. Squibb & Sons, L.l.c. Jul 7, 2025 | Consulting Fee | $2,400 |
| AstraZeneca Pharmaceuticals LP Jun 19, 2025 | Consulting Fee | $1,230 |
| Gilead Sciences, Inc. Apr 8, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4308212;GTF;11266051 | $760 |
| AbbVie Inc. Feb 14, 2025 | Consulting Fee | $7,975 |
| AbbVie Inc. Feb 14, 2025 | Travel and Lodging travel to LOS ANGELES, CA · in-kind | $130 |
| AbbVie Inc. Feb 14, 2025 | Travel and Lodging travel to LOS ANGELES, CA · in-kind | $8.00 |
| BioNTech SE Feb 6, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $17,347 |
| BioNTech SE Feb 6, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $1,198 |
| BioNTech SE Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind | $1,083 |
| BioNTech SE Feb 6, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind | $122 |
| AstraZeneca Pharmaceuticals LP Jan 26, 2025 | Consulting Fee | $685 |
| AstraZeneca Pharmaceuticals LP Jan 14, 2025 | Consulting Fee | $685 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $1,780,303 in research payments for these studies, mostly to the institutions running them.
- First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT03401385 - An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 …
AstraZeneca Pharmaceuticals LP - Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo Inc. · Completed · NCT04484142 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732 - A phase 1 study of SGNB6A in advanced solid tumors
Pfizer Inc. - A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Daiichi Sankyo Inc. · Recruiting · NCT06203210 - A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally A…
AstraZeneca Pharmaceuticals LP - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04656652
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.